Evonik Venture Capital
October 2016
Evonik Venture Capital October 2016 1 Table of contents 1. Evonik - - PowerPoint PPT Presentation
Evonik Venture Capital October 2016 1 Table of contents 1. Evonik at a glance 2. Evonik Venture Capital 3. Specialty Chemical segments 2 | October 2016 | Evonik Venture Capital 2015: Evonik in figures 18.2 % Employees December 31, 2015
Evonik Venture Capital
October 2016
Table of contents
Employees December 31, 2015
33,576
Profitability (adjusted EBITDA margin)
Adjusted EBITDA Return on capital Employed (ROCE)
16.6 %
sales
2015: Evonik in figures
| October 2016 | Evonik Venture CapitalLeading in Specialty Chemicals
Leading market positions in
80%
Strong customer intimacy and tailor-made solutions with
almost 90%
Most products with
small volume
but big impact in customers’ end products
~500 R&D projects
driving future sales potential Average
volume growth
from 2010 until 2015
more than 4%
in our growth segments2
Market leader Customer proximity Value proposition Innovation power Growth profile
| October 2016 | Evonik Venture CapitalConsistent execution of differentiated segment strategy
| October 2016 | Evonik Venture CapitalNutrition & Care Resource Efficiency Performance Materials Growth Efficiency €4,924 m €1,435 m / 29.1% €4,279 m €896 m / 20.9% Sales €3,435 m
€309 m / 9.0% Sales
Sales
Sales €13,507 m
€2,465 m Margin 18.2% ROCE 16.6%
2015 FinancialsEvonik Group 22 Business Lines grouped in 3 segments
Animal Nutrition Baby Care Health Care Personal Care Household Care Comfort & Insulation Interface & Performance Silica Crosslinkers Oil Additives Coating & Adhesive Resins High Performance Polymers Active Oxygens Silanes Coating Additives Catalysts Performance Intermediates Methacrylates Acrylic Products Functional Solutions Agrochemicals & Polymer Additives CyPlus Technologies
| October 2016 | Evonik Venture Capital 2015 financials; Business Lines ranked by turnoverNutrition & Care Resource Efficiency Performance Materials €4,924 m €1,435 m / 29.1% €4,279 m €896 m / 20.9% Sales €3,435 m
€309 m / 9.0% Sales
Sales
Growth strategy based on three strong pillars
Investments Innovation M&A
Sharpening of specialty chemicals portfolio Additional route for growth and value creation world-scale production plants erected and currently in ramp-up1
7
Acquisition of the Specialty & Coating Additives business of Air Products
~ 3.8 bn USD
Expansion of global production footprint Strengthen leading market positions worldwide Market- and customer-oriented R&D approach Product and process innovation R&D employees drive our innovation efforts across the group
~ 2,700
| October 2016 | Evonik Venture CapitalInnovation excellence: Evonik growth fields Leveraging our core competencies into highly attractive markets
| October 2016 | Evonik Venture CapitalEvonik Growth Fields Healthcare Solutions Smart Materials Sustainable Nutrition Cosmetic Solutions Membranes Advanced Food Ingredients Evonik Technology Competence Fields
Polymer Design Inorganic Particle Design Interfacial Technologies Coating & Bonding Technologies Catalytic Processes Biotechnology
Additional contribution to sales
Megatrends Health & Nutrition Globalization Resource Efficiency
more than €1 billion by 2025
Table of contents
Evonik Venture Capital strategic investor advantage
strategic, technical and commercial expertise:
technological expertise and infrastructure know-how of manufacturing processes and production scale-up market experience and global access expertise in patent strategies and on issues of intellectual property rights reputation and financial strength
| October 2016 | Evonik Venture CapitalEvonik Venture Capital investment focus
industrial coatings
and non-solvent coatings
monomers
nutrition
parenteral dosage
personal care applications
care and adult care
agents
additives for packaging, agrochemicals and plastic additives
Nutrition & Care Resource Effficency Performance Materials
| October 2016 | Evonik Venture CapitalEvonik Venture Capital investment outline
throughout the world, with a total volume of up to €100 million.
company. investments are driven by financial returns and strategic goals in innovative companies within key megatrends and new growth fields of Evonik typically in series A & B rounds of companies that have already entered the market
typically in syndication with other venture capital investors
| October 2016 | Evonik Venture CapitalEvonik Venture Capital portfolio (I)
| October 2016 | Evonik Venture CapitalEvonik Venture Capital portfolio (II)
Flexible composite pipes for the Oil & Gas industry.
Beta-glucan as nutritional supplement for feed- and food applications.
Bio-based synthetic oils for the lubricant and cosmetics industries.
Non-halogen, poly-phosphonates – fire-resistant plastics.
Bio-based nanocellulose for wound care and cosmetics.
Micro- and nano-optical structures for electronic applications.
Patient friendly solutions for correcting skeletal deformations.
Bio-absorbable closure device for large bore holes in the femoral artery.
3-D printed, biomechanically optimized insoles.
Focus on energy, water and materials in Europe and North America.
Focus on material focused green technology companies in China.
Focus on German early stage companies.
Focus on advanced materials companies in North America.
| October 2016 | Evonik Venture CapitalEvonik Venture Capital investment team
| October 2016 | Evonik Venture CapitalMain Office – Hanau, Germany Bernhard Mohr Managing Director Monika Braun Executive Assistant Petra Riva Executive Assistant Mona Friedrich Financial Analyst Anette Kübler Senior Venturing Manager Mark Redshaw Investment Director Jakob Wirbatz Investment Director Stephan Wolf Investment Manager Office – Essen, Germany Jens Busse Investment Manager Office – Parsippany, NJ Office – Woodlands, TX Lutz Stoeber Investment Director Eric Breese Investment Manager www.evonik.com/venturing
Table of contents
Nutrition & Care Business Line overview
| October 2016 | Evonik Venture CapitalAnimal Nutrition
Tryptophan
services for animal nutrition Personal Care
Household Care
Baby Care
Key products Main Applications Key products Main Applications Health Care
pharmaceutical synthesis
Comfort & Insulation
Interface & Performance
Resource Efficiency Business Line overview
| October 2016 | Evonik Venture CapitalSilica
Crosslinkers
composites, elastomers and non-solvent coatings Coating Additives
VOC, water based)
coatings
and highly solid industrial coatings Oil Additives
(viscosity modifiers)
Key products Main Applications Key products Main Applications Active Oxygens
chemical reactions
Catalysts
catalysts
petrochemicals
High Performance Polymers
fibres
Coating & Adhesive Resins
Silanes
Performance Materials Business Line overview
| October 2016 | Evonik Venture CapitalPerformance Intermediates
polymers Acrylic Polymers
Acrylite)
Acrylic Monomers
applications
(MMA) & application monomers
Key products Main Applications Key products Main Applications Agrochemicals
Functional Solutions
(e.g. sodium methylate)
production CyPlus Technologies